19 June 2013
Keywords: Cipla, India, Patent ruling, Sutent, Pfizer, Cipla Medpro, M&A
Article | 12 February 2013
The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating its earlier decision to revoke ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 February 2013
11 February 2013
18 June 2013
© 2013 thepharmaletter.com